Premium
Inhibitors of apoptosis proteins in prostate cancer cell lines
Author(s) -
McEleny Kevin R.,
Watson R. William G.,
Coffey Ronan N.T.,
O'Neill Amanda J.,
Fitzpatrick John M.
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10061
Subject(s) - du145 , lncap , xiap , cancer research , inhibitor of apoptosis , apoptosis , survivin , propidium iodide , biology , prostate cancer , microbiology and biotechnology , caspase , programmed cell death , cancer , biochemistry , genetics
BACKGROUND The caspases are the central executioners of apoptosis. The inhibitors of apoptosis proteins (IAPs) are a family of recently described caspase inhibitors. We hypothesised that tumor resistance to apoptosis could be due in part to IAP expression. METHODS The expression of NAIP, cIAP‐1, cIAP‐2, XIAP, and survivin was investigated in the prostate cancer cell lines LNCaP, PC3, and DU145. RNase protection assays and Western blotting were used to assess RNA and protein expression. Apoptotic susceptibility was determined using etoposide and assessed by propidium iodide (PI) DNA incorporation using flow cytometry. RESULTS DU145 and PC3 cells were more resistant to apoptosis than LNCaP cells. All the IAPs were identified in the cell lines with variation in IAP expression between different cell types. Immunohistochemistry demonstrated cIAP‐1 expression in PC3 cells was nuclear, while the expression of cIAP‐2 and XIAP was perinuclear. Growing LNCaP cells in charcoal‐stripped or androgen‐supplemented medium resulted in no alteration in IAP expression. CONCLUSIONS This study characterises the expression of IAP in three of the most commonly used prostate cancer cells. IAP may make an important contribution to apoptotic resistance in patients with prostate cancer. Prostate 51: 133–140, 2002. © 2002 Wiley‐Liss, Inc.